ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Necitumumab in Squamous NSCLC

Panelists: Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, University of Pittsburgh;Thomas E. Stinchcombe, MD, UNC; Anne S. Tsao, MD, MD Ande
Published: Saturday, Jun 06, 2015
For High-Definition, Click
Necitumumab is an IgG1 antibody with efficacy as a first-line treatment in individuals with advanced squamous cell non-small cell lung cancer (NSCLC), says Anne S. Tsao, MD. In the phase III SQUIRE trial 1093 patients were randomized to receive a platinum-based chemotherapy and gemcitabine with or without necitumumab. Although response rates and progression-free survival were not notable, a statistically significant improvement in overall survival (OS) was seen with the addition of necitumumab to chemotherapy. Median OS was approximately 11.5 months in those who were given necitumumab and 9.9 months in the chemotherapy-only cohort (P = .012).

With few options in the squamous cell setting, Tsao notes, the results are compelling. If approved it would likely be considered for frontline use. The FDA has scheduled an ODAC advisory hearing to discuss the biologics license application (BLA) for necitumumab in combination with gemcitabine and cisplatin as a first-line treatment for patients with locally advanced or metastatic squamous NSCLC. The meeting is scheduled for July 9, 2015.

The Southwest Oncology Group (SWOG) 0819 trial is currently assessing a subset of patients with at least 4 copies of the EGFR gene who received treatment with cetuximab, states Roy S. Herbst, MD. These individuals were identified by fluorescence in situ hybridization (FISH) assay and are thought to have a greater benefit from anti-EGFR therapy. While results that either support or refute this theory will not be available for a few years, it may be practical to search for similar biomarker assays in necitumumab studies, comments Herbst.

Slider Left
Slider Right
For High-Definition, Click
Necitumumab is an IgG1 antibody with efficacy as a first-line treatment in individuals with advanced squamous cell non-small cell lung cancer (NSCLC), says Anne S. Tsao, MD. In the phase III SQUIRE trial 1093 patients were randomized to receive a platinum-based chemotherapy and gemcitabine with or without necitumumab. Although response rates and progression-free survival were not notable, a statistically significant improvement in overall survival (OS) was seen with the addition of necitumumab to chemotherapy. Median OS was approximately 11.5 months in those who were given necitumumab and 9.9 months in the chemotherapy-only cohort (P = .012).

With few options in the squamous cell setting, Tsao notes, the results are compelling. If approved it would likely be considered for frontline use. The FDA has scheduled an ODAC advisory hearing to discuss the biologics license application (BLA) for necitumumab in combination with gemcitabine and cisplatin as a first-line treatment for patients with locally advanced or metastatic squamous NSCLC. The meeting is scheduled for July 9, 2015.

The Southwest Oncology Group (SWOG) 0819 trial is currently assessing a subset of patients with at least 4 copies of the EGFR gene who received treatment with cetuximab, states Roy S. Herbst, MD. These individuals were identified by fluorescence in situ hybridization (FISH) assay and are thought to have a greater benefit from anti-EGFR therapy. While results that either support or refute this theory will not be available for a few years, it may be practical to search for similar biomarker assays in necitumumab studies, comments Herbst.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x